StockNews.com Lowers CymaBay Therapeutics (NASDAQ:CBAY) to Sell

StockNews.com downgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) from a hold rating to a sell rating in a research note issued to investors on Wednesday. CBAY has been the subject of several other research reports. HC Wainwright increased their target price on CymaBay Therapeutics from $10.00 to $12.00 in a research report on […]

Related Keywords

Canada ,William Blair ,Dennisd Kim ,Charles Mcwherter ,Nasdaq ,Great West Life Assurance Co ,Dorsey Wright Associates ,Securities Exchange Commission ,Royal Bank ,Cymabay Therapeutics Inc ,Cantor Fitzgerald ,Verition Fund Management ,Cymabay Therapeutics ,Free Report ,Moderate Buy ,Bay Therapeutics Trading Down ,Bay Therapeutics ,Get Free Report ,Exchange Commission ,Street Group ,West Life Assurance ,Cymabay Therapeutics Daily ,